Australia's most trusted
source of pharma news
Thursday, 30 July 2026
Posted 30 July 2026 AM
The new Australian CEO of GSK Luke Miels yesterday brazenly unveiled a three-year costing-saving program just six months into the job, but it was his much more low-key announcement to relocate the company's R&D headquarters, that has sparked a fierce response on LinkedIn.
GSK said it would establish a new flagship R&D Centre on the UK's Cambridge Biomedical Campus, closing its historic R&D hub in Stevenage.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.